TREATMENT SEQUENCING PATTERNS AND COSTS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：4
|
作者：
Potluri, R. [1 ]
Farr, A. M. [2 ]
Hirji, I [3 ]
Davis, C. [4 ]
Bhandari, H. [5 ]
Oukessou, A. [4 ]
机构：
[1] SmartAnalyst Inc, New York, NY USA
[2] Truven Hlth Analyt, Bethesda, MD USA
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] SmartAnalyst India Pvt Ltd, Gurgaon, India
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1134
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN118
引用
收藏
页码：A450 / A450
页数：1
相关论文
共 50 条
  • [41] Optimal sequencing in the management of relapsed/refractory myeloma patients
    Moreau, Philippe
    HEMASPHERE, 2018, 2 : 125 - 126
  • [42] Treatment sequencing patterns for relapsed refractory multiple myeloma (RRMM) in the era of new therapies in a single center institution.
    Tungesvik, Alexandre
    Sudalagunta, Praneeth Reddy
    Huang, Jessica
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebecca
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth H.
    Brayer, Jason B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Michael, M.
    Bruns, I.
    Boelke, E.
    Zohren, F.
    Czibere, A.
    Safaian, N. N.
    Ncumann, F.
    Haas, R.
    Kobbe, G.
    Fenk, R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (01) : 13 - 19
  • [44] Bendamustine in patients with relapsed or refractory multiple myeloma
    M Michael
    I Bruns
    E Bölke
    F Zohren
    A Czibere
    N N Safaian
    F Neumann
    R Haas
    G Kobbe
    R Fenk
    European Journal of Medical Research, 15
  • [45] Management of patients with relapsed/refractory multiple myeloma
    Ludwig, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 3 - 4
  • [46] A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
    Cook, Gordon
    Zweegman, Sonja
    Mateos, Maria-Victoria
    Suzan, Florence
    Moreau, Philippe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 121 : 74 - 89
  • [47] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Janet A. Parsons
    Nicole R. Greenspan
    Natalie A. Baker
    Chris McKillop
    Lisa K. Hicks
    Olivia Chan
    BMC Cancer, 19
  • [48] Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
    Ailawadhi, Sikander
    Dersarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert
    CLINICAL THERAPEUTICS, 2019, 41 (03) : 477 - 493
  • [49] Targeted Therapy Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    ONCOLOGY-NEW YORK, 2021, 35 (05): : 284 - 287
  • [50] Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients
    Mangiacavalli, Silvia
    Pica, GianMatteo
    Varettoni, Marzia
    Lazzarino, Mario
    Corso, Alessandro
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (03) : 240 - 241
12345